Valtrex transmission indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Aug. 29 approval of GSK's Valtrex (valacyclovir) for reduction of the risk of heterosexual transmission of genital herpes in immunocompetent patients follows the Antiviral Drugs Advisory Committee's May 14 recommendation on restricting the patient population. GSK had been seeking a broader indication that did not specify sexual orientation or immune status. The company is developing a patient education brochure, to be available in October, emphasizing safe-sex practices with the use of Valtrex. FDA cleared the agent April 1 for suppression of recurrent genital herpes in HIV-infected patients (1Pharmaceutical Approvals Monthly April 1, 2003, In Brief)...
You may also be interested in...
GSK Valtrex gains indication, another pending
GlaxoSmithKline's Valtrex (valacyclovir) clears FDA for suppression of recurrent genital herpes in HIV-infected patients April 1. FDA's Antiviral Drugs Advisory Committee will consider another supplemental indication for Valtrex May 14 - use as suppressive therapy to reduce the risk of transmitting genital herpes. GSK submitted the risk reduction sNDA Oct. 31, 2002 and expects a standard revie
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.